Introduction: To report 2-year outcomes of intravitreal injection of high-dose conbercept (1 mg 2+PRN scheme) for subjects with myopic choroidal neovascularization (mCNV) and idiopathic choroidal neovascularization (iCNV) by optical coherence tomography angi-ography (OCTA) follow-up. Methods: A total of 38 subjects (38 eyes) were enrolled in this retrospective study, which were divided into group A (mCNV, 20 subjects, 20 eyes) and group B (iCNV, 18 subjects,18 eyes). All subjects received 1.0 mg of conbercept intravitre-ally at diagnosis and again 35 days later. Additional conbercept injection was administered upon findings of decreased best-corrected visual acuity (BCVA); metamorphosis aggrava-tion, macular hemorrhage, or edema; increased central retinal thickness (CRT); or leakage observed by fluorescein angiography (FA). The BCVA, CRT, and CNV area of the two groups were evaluated at baseline and at 1, 2, 4, 6, 12, and 24 months after surgery. Results: The BCVA of group A improved from 0.31 ±0.16 logMAR at baseline to 0.12 ± 0.03logMAR at the final follow-up (P 0.05). Con-clusion: Intravitreal injection of conbercept (1 mg 2+PRN scheme) is effective for treating patients with mCNV or iCNV, which can improve and stabilize vision as well as dramatical-ly alleviate metamorphopsia.

The Author(s). Published by S. Karger AG, Basel